Answers are grounded in this paper and cite their sources.
This review discusses the role of N-acetylglucosaminyltransferase V in cancer progression, suggesting potential therapeutic strategies.
N-Acetylglucosaminyltransferase V (GnT-V) is a pivotal glycosyltransferase catalyzing the formation of β1–6 branched N-glycans, a structural modification intimately linked to cancer malignancy. While elevated GnT-V expression correlates with metastasis in breast, gastric, and colorectal cancers, its function is context-dependent, predicting distinct outcomes in lung and bladder cancers. Crucially, the oncogenic potential of GnT-V is not isolated but is dynamically regulated by its competitive interplay with GnT-III and cooperation with α1,6-fucosyltransferase 8 (Fut8). Distinct from previous summaries, this review systematically dissects the molecular signaling networks driving these pathologies. Beyond well-known pathways like Wnt/β-catenin and receptor stabilization (EGFR, HER-2), we highlight emerging evidence regarding the role of GnT-V in promoting resistance to anoikis and facilitating immune evasion. Furthermore, we detail how GnT-V orchestrates the epithelial–mesenchymal transition (EMT) and cytoskeletal remodeling via the RhoA/Rac1 axis. By integrating these signaling networks with the enzyme's regulatory environment, we provide a comprehensive roadmap of GnT-V pathogenesis and propose that targeting the GnT-V/GnT-III balance represents a promising strategy for precise cancer diagnosis and therapy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: